Australia's Noxopharm hits one-month high after CEO appointment

Noxopharm

05/01/2022 02:25

** Shares of Noxopharm Ltd  NOX.AX  rise as much as 6.1% to
A$0.435, their highest since Dec. 6
    ** Drug developer says it has appointed Dr. Gisela Mautner
as its chief executive, effective from Feb. 1  urn:newsml:reuters.com:*:nFWN2TK0Y2
    ** Says Mautner, currently its chief medical officer, will
serve as the executive managing director of board
    ** Says current CEO Graham Kelly will remain on board as a
non-executive director and assume a consultant role   
    ** Stock fell 20.41% in 2021

 (Reporting by Archishma Iyer)
 ((Archishma.Iyer@thomsonreuters.com;))